Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Estrogen Receptor–Positive Breast Cancer ER-positive, HER2-negative breast cancer,
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …

Background In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole
resulted in significantly longer progression-free survival than letrozole alone among …

Several new systemic therapy options have become available for patients with metastatic
breast cancer, which have led to improvements in survival. In addition to patient and clinical …

Combining existing drug therapy is essential in developing new therapeutic agents in
disease prevention and treatment. In preclinical investigations, combined effect of certain …

Breast cancer is the most commonly occurring cancer in women. There were over two-
million new cases in world in 2018. It is the second leading cause of death from cancer in …

Despite tremendous resources being invested in prevention and treatment, breast cancer
remains a leading cause of cancer deaths in women globally. The available treatment …

Importance Breast cancer mortality in the US declined between 1975 and 2019. The
association of changes in metastatic breast cancer treatment with improved breast cancer …

The natural history of hormone receptor–positive breast cancer tends to be more favorable
than other subtypes such as human epidermal growth factor receptor 2–amplified and triple …

Background: Endocrine treatment is one of the most effective therapies for estrogen receptor-
positive breast cancer. However, most tumors will develop resistance to endocrine therapy …